148 related articles for article (PubMed ID: 21470325)
1. Alterations in the RB1 pathway in low-grade diffuse gliomas lacking common genetic alterations.
Kim YH; Lachuer J; Mittelbronn M; Paulus W; Brokinkel B; Keyvani K; Sure U; Wrede K; Nobusawa S; Nakazato Y; Tanaka Y; Vital A; Mariani L; Ohgaki H
Brain Pathol; 2011 Nov; 21(6):645-51. PubMed ID: 21470325
[TBL] [Abstract][Full Text] [Related]
2. Deregulation of the TP53/p14ARF tumor suppressor pathway in low-grade diffuse astrocytomas and its influence on clinical course.
Watanabe T; Katayama Y; Yoshino A; Komine C; Yokoyama T
Clin Cancer Res; 2003 Oct; 9(13):4884-90. PubMed ID: 14581362
[TBL] [Abstract][Full Text] [Related]
3. The p15(INK4b)/p16(INK4a)/RB1 pathway is frequently deregulated in human pituitary adenomas.
Ogino A; Yoshino A; Katayama Y; Watanabe T; Ota T; Komine C; Yokoyama T; Fukushima T
J Neuropathol Exp Neurol; 2005 May; 64(5):398-403. PubMed ID: 15892297
[TBL] [Abstract][Full Text] [Related]
4. Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis.
Edamoto Y; Hara A; Biernat W; Terracciano L; Cathomas G; Riehle HM; Matsuda M; Fujii H; Scoazec JY; Ohgaki H
Int J Cancer; 2003 Sep; 106(3):334-41. PubMed ID: 12845670
[TBL] [Abstract][Full Text] [Related]
5. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
[TBL] [Abstract][Full Text] [Related]
6. Frequent epigenetic inactivation of Rb1 in addition to p15 and p16 in mantle cell and follicular lymphoma.
Chim CS; Wong KY; Loong F; Lam WW; Srivastava G
Hum Pathol; 2007 Dec; 38(12):1849-57. PubMed ID: 17900658
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of p14ARF, p15INK4b, and p16INK4a inactivation in malignant peripheral nerve sheath tumors.
Endo M; Kobayashi C; Setsu N; Takahashi Y; Kohashi K; Yamamoto H; Tamiya S; Matsuda S; Iwamoto Y; Tsuneyoshi M; Oda Y
Clin Cancer Res; 2011 Jun; 17(11):3771-82. PubMed ID: 21262917
[TBL] [Abstract][Full Text] [Related]
8. Promoter hypermethylation profile of cell cycle regulator genes in pituitary adenomas.
Yoshino A; Katayama Y; Ogino A; Watanabe T; Yachi K; Ohta T; Komine C; Yokoyama T; Fukushima T
J Neurooncol; 2007 Jun; 83(2):153-62. PubMed ID: 17216555
[TBL] [Abstract][Full Text] [Related]
9. Preferentially different mechanisms of inactivation of 9p21 gene cluster in liver fluke-related cholangiocarcinoma.
Chinnasri P; Pairojkul C; Jearanaikoon P; Sripa B; Bhudhisawasdi V; Tantimavanich S; Limpaiboon T
Hum Pathol; 2009 Jun; 40(6):817-26. PubMed ID: 19200577
[TBL] [Abstract][Full Text] [Related]
10. p16 is a major inactivation target in hepatocellular carcinoma.
Jin M; Piao Z; Kim NG; Park C; Shin EC; Park JH; Jung HJ; Kim CG; Kim H
Cancer; 2000 Jul; 89(1):60-8. PubMed ID: 10897001
[TBL] [Abstract][Full Text] [Related]
11. Frequent BRAF gain in low-grade diffuse gliomas with 1p/19q loss.
Kim YH; Nonoguchi N; Paulus W; Brokinkel B; Keyvani K; Sure U; Wrede K; Mariani L; Giangaspero F; Tanaka Y; Nakazato Y; Vital A; Mittelbronn M; Perry A; Ohgaki H
Brain Pathol; 2012 Nov; 22(6):834-40. PubMed ID: 22568401
[TBL] [Abstract][Full Text] [Related]
12. CDKN2A-CDKN2B deletion defines an aggressive subset of cutaneous T-cell lymphoma.
Laharanne E; Chevret E; Idrissi Y; Gentil C; Longy M; Ferrer J; Dubus P; Jouary T; Vergier B; Beylot-Barry M; Merlio JP
Mod Pathol; 2010 Apr; 23(4):547-58. PubMed ID: 20118908
[TBL] [Abstract][Full Text] [Related]
13. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
[TBL] [Abstract][Full Text] [Related]
14. Frequent alterations of the p14(ARF) and p16(INK4a) genes in primary central nervous system lymphomas.
Nakamura M; Sakaki T; Hashimoto H; Nakase H; Ishida E; Shimada K; Konishi N
Cancer Res; 2001 Sep; 61(17):6335-9. PubMed ID: 11522621
[TBL] [Abstract][Full Text] [Related]
15. Concurrent inactivation of RB1 and TP53 pathways in anaplastic oligodendrogliomas.
Watanabe T; Yokoo H; Yokoo M; Yonekawa Y; Kleihues P; Ohgaki H
J Neuropathol Exp Neurol; 2001 Dec; 60(12):1181-9. PubMed ID: 11764090
[TBL] [Abstract][Full Text] [Related]
16. Lack of germ-line mutations of CDK4, p16(INK4A), and p15(INK4B) in families with glioma.
Gao L; Liu L; van Meyel D; Cairncross G; Forsyth P; Kimmel D; Jenkins RB; Lassam NJ; Hogg D
Clin Cancer Res; 1997 Jun; 3(6):977-81. PubMed ID: 9815774
[TBL] [Abstract][Full Text] [Related]
17. Differential effect of epigenetic alterations and genomic deletions of CDK inhibitors [p16(INK4a), p15(INK4b), p14(ARF)] in mantle cell lymphoma.
Hutter G; Scheubner M; Zimmermann Y; Kalla J; Katzenberger T; Hübler K; Roth S; Hiddemann W; Ott G; Dreyling M
Genes Chromosomes Cancer; 2006 Feb; 45(2):203-10. PubMed ID: 16258956
[TBL] [Abstract][Full Text] [Related]
18. Alterations of p14
López F; Sampedro T; Llorente JL; Hermsen M; Álvarez-Marcos C
Pathol Oncol Res; 2017 Jan; 23(1):63-71. PubMed ID: 27377733
[TBL] [Abstract][Full Text] [Related]
19. Investigation of germline PTEN, p53, p16(INK4A)/p14(ARF), and CDK4 alterations in familial glioma.
Tachibana I; Smith JS; Sato K; Hosek SM; Kimmel DW; Jenkins RB
Am J Med Genet; 2000 May; 92(2):136-41. PubMed ID: 10797439
[TBL] [Abstract][Full Text] [Related]
20. Expression Analysis of Genes Involved in the RB/E2F Pathway in Astrocytic Tumors.
Ferreira WA; Araújo MD; Anselmo NP; de Oliveira EH; Brito JR; Burbano RR; Harada ML; Borges Bdo N
PLoS One; 2015; 10(8):e0137259. PubMed ID: 26317630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
